Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Lung Cancer On The Rise: Understanding Why People Are Getting Diagnosed…
Browsing: Non-Small Cell Lung Cancer
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Germline Mutations In Patients With Lung Cancer: Study Had 104 Patients…
Dr. Paul Paik, MD, discusses the future of Tepotinib. Background: MET exon 14 skipping (METex14) mutations – reported in 3~4%…
Dr. Paul K. Paik, MD, on the Phase II study of Tepotinib. Background: MET exon 14 skipping (METex14) mutations -…
Dr. Sanjay Popat discusses if East Asian patients tolerate Brigatinib any differently than Crizotinb. Background: We report an analysis of…
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses Targeting CEACAM1: Idea Is To Block CEACAM Connections & Doing So Gives…
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance.
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With…
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond…
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Broadening Eligibility Criteria For Trials: A Lot Of Eligibility…
GRACE – Global Resource for Advancing Cancer Education Published on Feb 14, 2017 Dr. Luis Raez, MD FACP FCCP, Chief…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 7, 2016 Spanish Lung Cancer Library: Antonio Calles, MD,…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 25, 2016 Dr. Rafael Santana-Davila, Assistant Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 25, 2016 Dr. Rafael Santana-Davila, Assistant Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 12, 2016 Spanish Lung Cancer Library: Dr. Brian Hunis,…
GRACE – Global Resource for Advancing Cancer Education Published on Aug 23, 2017 Lung Cancer Video Library http://cancerGRACE.org/
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 30, 2018 Dr. Vamsidhar Velcheti, Hematology and Medical Oncology…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 30, 2018 Dr. Vamsidhar Velcheti, Hematology and Medical Oncology…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 15, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Karen Kelly, Associate Director for Clinical…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 15, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 15, 2019 For more, please visit http://cancerGRACE.org/. To join…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 15, 2019 For more, please visit http://cancerGRACE.org/. To join…
GRACE – Global Resource for Advancing Cancer Education Published on Aug 22, 2018 Drs Zofia Piotrowska, H. Jack West, and…
test video spanish upload
We are pleased to share with you the videos from the live webcast. In this 5th video, the panel opens…
We are pleased to share with you the videos from the live webcast. In this 4th video, Dr. H. Jack…
We are pleased to share with you the videos from the live webcast. In this 3rd video, Dr. Eric Vallieres…
We are pleased to share with you the videos from the live webcast. In this 2nd video, Dr. Puneeth Iyengar…
We are pleased to share with you the videos from the live webcast. In this first video, Dr. West introduces…
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1…
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used…
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as…
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1…
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced…
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an…
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in…
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at…
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance…
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling…
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from…
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance…
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely…
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02 This on-demand webcast examines the efficacy and safety, indications, and cost utility of…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend…
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for…
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic…
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for…
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what…
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with…
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Drs. Langer, Aggarwal, Bazhenova, and…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses EGFR…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Helen Ross discusses the…
Sanjay Popat, M.D., of The Royal Marsden Hospital Discusses ALTA-1L Trial CNS Efficacy. At ESMO Oncology Conference – Munich, Germany…
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states…
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of…
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination…
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a…
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
GRACE – Global Resource for Advancing Cancer Education Published on Feb 25, 2016 Dr. Gerard Silvestri, Medical University of South…
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer…
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses precision medicine at the European Lung Cancer…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD,…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD,…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the…
Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dean Fennell, PhD, FRCP, of the University of…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, talks about delivering personalized therapy for…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, discusses upcoming therapeutic targets for mesothelioma…
With the approval of new therapies that are restricted based on PD-L1 expression, there are many different assays to test…
Mamta Ruparel, MBBS, MRCP, of University College London, London, UK, discusses the current data and guidelines associated with the finding…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Capuzzo, MD, PhD, of AUSL della Romagna,…
In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Keith Kerr, MB, ChB, FRCPath, FRCPE, from…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of…
Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, discusses single target therapies in thoracic oncology and beyond…
Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest…
The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed…
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small…
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from…
Steroids were previously administered as a form of treatment for many different conditions, including cancer. However, the previous usage of…
The use of sequential single-gene testing to detect genomic alterations in metastatic non-small cell lung cancer (NSCLC) can be costly,…
The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell…
The ATLANTIC trial (NCT02087423) is currently underway to determine the effects of durvalumab on patients with advanced non-small cell lung…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses smoking, asbestos, radon and other risk factors for lung cancer.
Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in…
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio…
Mohammad Jahanzeb, MD, FACP, explains what he might do in sequencing therapies as a result of Keynote 189 and Keynote…
Mohammad Jahanzeb, MD, FACP, explains the significance of Keynote 42 from Annual Meeting 2018.
Mohammad Jahanzeb, MD, FACP, shares his thoughts on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin,…
Mohammad Jahanzeb, MD, FACP, explains the results of Keynote 189, PDL-1 expression and patient selection at Annual Meeting 2018.
David R. Gandara, MD, talks about the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line…
David R. Gandara, MD, explains drug sequencing as a result of Keynote 189 and 42 results at Annual Meeting 2018.
Joan Schiller, MD, talks about the Keynote trials presented and whether they will impact her choice of therapy for squamous…
David R. Gandara, MD, explains what will change about patient selection as a result of Keynote 42 at Annual Meeting…
Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting…
David R. Gandara, MD, talks about continuing pemextrexed maintenance
David R. Gandara, MD, explains whether Keynote 189 impacted view of PDL-1 expression and patient selection at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, discusses if patient selection will change as a result of Keynote 42
David R. Gandara, MD, shares exciting new developments in lung cancer
Roy S. Herbst, MD, PhD, shares his thoughts on whether to continue pemetrexed maintenance after successful treatment of the patient…
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell…
Joan Schiller, MD, shares her thoughts regarding the results of Keynote 42 presented at the 2018 Annual Meeting and how…
Roy S. Herbst, MD, PhD, shares his thoughts on whether Keynote 189 impacted view of PDL-1 expression and patient selection.
Edgardo S. Santos, MD, FACP, shares his opinion on continued pemetrexed maintenance.
Joan Schiller, MD, shares her opinion on continuing pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
Joan Schiller, MD, shares Keynote 189 and whether the data impacts her view of PDL-1 expression and patient selection at…
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his…
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as…
Marianne Nicolson, MD, FRCP, BSc, MBChB, of NHS Grampian, Aberdeen, UK, gives an overview of a session discussing lung cancer…
Mariam Jamal-Hanj, BSc, MBBS, PhD, of University College London, London, UK, discusses her talk regarding intra-tumor heterogeneity within lung cancer…
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the…
Lung cancer is the leading cause of cancer mortality in the United States, and low-dose CT scans are advised as…
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva)…
An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize…
The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung…
The management of patients with metastatic non-small cell lung cancer (NSCLC) is a field which has seen drastic improvement in…
Liviu Niculescu, MD PhD, explains Frontline Trials to Show if Alunbrig is Superior Figure What is the Best Sequencing for…
Liviu Niculescu, MD PhD, explains Patients Have Other Companies & Research Groups Working with Colleagues to Advance Life of Patients…
Liviu Niculescu, MD PhD, explains Newly Diagnosed Patients with ALK-Positive Disease Are Being Randomized with Alunbrig at Annual Meeting 2018
Liviu Niculescu, MD PhD, Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate at Annual Meeting 2018
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III…
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.
Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve…
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is…
Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases…
Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery,…
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who…
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between…
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority…
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for…
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance…
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing…
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the reasons behind using adjuvant chemotherapy for early stage NSCLC patients. Clinical…
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung…
In this thirteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon…
In this eleventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon…
In this fourteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon…
In this sixteenth and final video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents…
On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung…
On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung…
On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung…